Drug Profile


Alternative Names: QBECO SSI; Site specific immunomodulator - Qu Biologics

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Qu Biologics
  • Class Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Colorectal cancer

Most Recent Events

  • 19 Apr 2017 Efficacy data from a phase I/IIb trial in Crohn’s disease released by Qu Biologics
  • 22 Mar 2017 Immunogenicity data from a phase II clinical trial in Ulcerative colitis released by Qu Biologics
  • 03 Mar 2017 Qu Biologics plans a follow-on phase II trial for Crohn's Disease in Canada in late 2017 or early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top